Hopital Prive Des Cotes D'armor
- Address
- lock Available on a paid plan
Digestive System Cancers
The oncology team at Hopital Prive Des Cotes D'armor focuses on digestive system diseases, especially colorectal cancer and colon carcinoma, aiming to test new therapeutic combinations and improve disease monitoring.
- Evaluation of chemotherapy plus targeted agents
- ctDNA‑guided treatment strategies after surgery
- Development of antibody‑drug conjugates for resistant tumors
Ongoing studies seek to extend progression‑free survival and provide alternatives for patients whose disease no longer responds to standard care.
Hormone Receptor Positive Breast Cancer
Research on hormone receptor positive breast cancer includes early‑stage ER+/HER2‑ disease and metastatic HR+ HER2‑ tumors, evaluating novel endocrine‑based regimens and targeted inhibitors.
- Combination of CDK4/6 inhibitors with fulvestrant
- PIK3CA‑mutation specific agents such as alpelisib
- Maintenance strategies after initial response
The goal is to delay progression and improve quality of life for patients receiving endocrine therapy.
Triple‑Negative Breast Cancer
The site investigates treatment options for triple‑negative metastatic breast cancer, including antibody‑drug conjugates and novel chemotherapy combinations for patients with limited options.
- Sacituzumab govitecan efficacy versus physician’s choice
- Biomarker‑driven patient selection after neoadjuvant therapy
- Objective response assessment using RECIST criteria
These trials aim to increase response rates and extend survival in this aggressive breast cancer subtype.
Muscle‑Invasive Bladder Cancer
Studies on muscle‑invasive bladder cancer evaluate peri‑operative immunotherapy combined with standard chemotherapy, comparing outcomes with placebo in patients eligible for cisplatin.
- Pembrolizumab added to neoadjuvant chemotherapy
- Impact on event‑free survival after radical cystectomy
- Safety and efficacy of checkpoint inhibition versus placebo
The research seeks to improve surgical cure rates and reduce recurrence for high‑risk bladder cancer patients.
Advanced Gynecologic Cancers
Clinical investigations target advanced ovarian, fallopian‑tube and peritoneal cancers, testing PARP inhibitor maintenance and anti‑angiogenic strategies after optimal cytoreductive surgery.
- Paclitaxel‑carboplatin followed by niraparib maintenance
- Combination of bevacizumab with chemotherapy and subsequent niraparib
- Evaluation of progression‑free survival at 24 months
These efforts aim to prolong remission and offer new treatment pathways for patients with high‑grade gynecologic malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 140 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 137 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hopital Prive Des Cotes D'armor
lock Showing 1 of 89 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| "TUC-TOC": Tucatinib in combination with Oral Etoposide (VP16) - Trastuzumab in Patients with metastatic HER2+ Breast cancer after progression under Tucatinib-Capecitabine-Trastuzumab or toxicity related to capecitabine: a multicenter Phase II | Institut Curie | Phase II | Recruiting | Dec 2023 | — |
IMP list
lock Showing 1 of 140 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paclitaxel | 16 | Unknown | 2019-03-14 | 2026-04-29 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.